Active Biotech Interim report January – September 2019

                                                                                                                           
Third quarter in brief
A new business plan for laquinimod and tasquinimod, based on the extensive preclinical and clinical data previously generated, is in progressData on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease was presented at the International congress of Parkinson’s disease and movement disordersEvents after the end of the periodThe first patient in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors has been dosedPreclinical data on naptumomab estafenatox was presented at the Society for Immunotherapy of Cancer’s 34th Annual MeetingFinancial summaryFor further information, please contact:The report is also available at www.activebiotech.com.AttachmentActive Biotech Interim report January – September 2019

Disclaimer & Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.